<--- Back to Details
First PageDocument Content
Biology / Medicine / Biotechnology / Specialty drugs / Peptide hormones / Recombinant proteins / Eli Lilly and Company / Trastuzumab / Kiran Mazumdar-Shaw / Biosimilar / Biocon / Biopharmaceutical
Date: 2016-08-03 03:39:33
Biology
Medicine
Biotechnology
Specialty drugs
Peptide hormones
Recombinant proteins
Eli Lilly and Company
Trastuzumab
Kiran Mazumdar-Shaw
Biosimilar
Biocon
Biopharmaceutical

Biocon Limited: Q1 FY17 Earnings Call Transcript July 22, 2016 Participants from Biocon’s Senior Management Team Kiran Mazumdar Shaw: Chairperson and Managing Director Arun Chandravarkar: CEO & Jt. Managing Director

Add to Reading List

Source URL: www.biocon.com

Download Document from Source Website

File Size: 99,85 KB

Share Document on Facebook

Similar Documents

CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium

CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium

DocID: 1vhgc - View Document

STATE BIOSIMILAR SUBSTITUTION LAWS Please note: This chart is for informational purposes only and does not constitute legal advice or opinions regarding any specific facts relating to the substitution of biosimilars. You

STATE BIOSIMILAR SUBSTITUTION LAWS Please note: This chart is for informational purposes only and does not constitute legal advice or opinions regarding any specific facts relating to the substitution of biosimilars. You

DocID: 1t1RV - View Document

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

27 JANUARY 2016 BIOSIMILARS DEVELOPMENT - FROM PRE-CLINIC TO MARKET Several biological products, altogether worth over US$60 billion annual sales, are encountering patent expiry byThis opens up the opportunity for

27 JANUARY 2016 BIOSIMILARS DEVELOPMENT - FROM PRE-CLINIC TO MARKET Several biological products, altogether worth over US$60 billion annual sales, are encountering patent expiry byThis opens up the opportunity for

DocID: 1rnQJ - View Document

January 8, 2016  BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion Immuno­Oncology Deal In yet

January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion Immuno­Oncology Deal In yet

DocID: 1rlhw - View Document